BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 23, 2010
View Archived Issues
AstraZeneca reports results from Q4 2009 and the year's R&D highlights
Read More
Alnylam initiates phase IIb trial of ALN-RSV01 in RSV-infected lung transplant patients
Read More
Curemark's CM-AT autism treatment obtains FDA fast track status
Read More
DNA prime/rAd5 boost vaccine regimen safe and immunogenic in HIV
Read More
Dual-acting NMDA antagonist neuroprotective in rat model of spinal cord injury
Read More
EnzymeRx provides clinical update on pegsitacase
Read More
Dual PI3K/mTOR inhibitor with potent preclinical antitumor activity enters phase I trial
Read More
Merck T-type calcium channel antagonists effective in models of CNS disorders
Read More
Novel HSP90 inhibitors identified by sanofi-aventis
Read More
Ranbaxy Laboratories discloses new antibacterial agents
Read More
Avexa discovers HIV integrase inhibitors for AIDS therapy
Read More
FDA approves once-daily Mirapex ER for early Parkinson's disease
Read More
PPARdelta agonists discovered at sanofi-aventis
Read More
Ceragenix and BexPharm enter into agreement for EpiCeram
Read More
Viamet and Novartis partner for metalloenzyme inhibitors
Read More
Hematopoietic prostaglandin-D2 synthase inhibitors claimed by Pfizer for asthma therapy
Read More
BioSante reports phase III LibiGel safety data
Read More
Concert Pharmaceuticals describes new GABA(A) receptor inverse agonists
Read More
GSK and FDA present safety update on Avandia for type 2 diabetes
Read More
Takeda and Affymax begin phase III trial of Hematide in chronic renal failure
Read More
FDA grants marketing approval for Gilead's Cayston for CF patients with P. aeruginosa
Read More
Amylin and Takeda to begin phase III trial of pramlintide/metreleptin in obesity
Read More
Lilly, Merck and Pfizer form Asian Cancer Research Group
Read More
Additional agents included in strategic collaboration of ExonHit and Allergan
Read More
Cyto Pulse obtains Swedish approval for phase I HIV/DNA vaccine trial
Read More